Tuberculosis-Associated Fatal Hemophagocytic Syndrome in a Patient with Lymphoma Treated with Fludarabine

Autor:	Alejandro Ruiz-Argüelles, Javier Garcés-Eisele, Sergio Sanchez-Sosa, Guillermo J. Ruiz-Argüelles, Daniel Arizpe-Bravo, Samuel Ponce-de-León
Rok vydání:	1998
Předmět:	Adult Cancer Research medicine.medical_specialty Miliary tuberculosis Tuberculosis Histiocytosis Non-Langerhans-Cell Antineoplastic Agents Gastroenterology Fatal Outcome Prednisone Internal medicine medicine Humans Chlorambucil business.industry Lymphoma Non-Hodgkin Complete remission Hematology medicine.disease Fludarabine Lymphoma Oncology Immunology Female Complication business Immunosuppressive Agents Vidarabine medicine.drug
Zdroj:	Leukemia & Lymphoma. 28:599-602
ISSN:	1029-2403 1042-8194
DOI:	10.3109/10428199809058369
Popis:	A patient with a stage IV high-grade non-Hodgkin's lymphoma who developed a fatal hemophagocytic syndrome is presented: When the patient had achieved complete remission and receiving fludarabine and chlorambucil/prednisone, she developed miliary tuberculosis, the CD4+ T-cell count then being 50/microL; the hemophagocytic syndrome ensuing at this point was fatal. Speculations about the predisposing factors that could have led to this complication are discussed focusing on the severe cellular immunosuppression which developed probably related to the use of fludafabine: it could be useful in the future to use anti-tuberculous prophylaxis in selected patients treated with this purine nucleoside analog.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c31067945120f7ac0f66ef6d66c57140 https://doi.org/10.3109/10428199809058369 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.